Jim Cramer reviewed Pfizer Inc. (NYSE:PFE) while breaking down 16 stocks for a market facing higher energy costs and economic ...
Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Click here to find out why PFE stock is ...
Up until recently, the stock has been a chronic underperformer.
In March 2026, Pfizer and partner Valneva reported that their investigational 6‑valent OspA-based Lyme disease vaccine ...
TrumpRx/MFN pricing risks could pressure margins despite 9.3x fwd P/E, 6.27% dividend and pipeline gains. Read the latest ...
After years of lagging the market, has Pfizer (PFE +1.19%) finally found a spark? With unimpressive financial results and ...
Pfizer has quietly built momentum in 2026 and Guggenheim just raised its price target to $36 while reiterating a Buy rating.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results